New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo; Robert A. Baiocchi; Amer Beitinjaneh; Sridhar Chaganti; Sylvain Choquet; Daan Dierickx; Rajani Dinavahi; Laurence Gamelin; Armin Ghobadi; Norma Guzman-Becerra; Manher Joshi; Aditi Mehta; Sarah Nikiforow; Ran Reshef; Wei Ye; Susan Prockop

doi:10.1182/blood-2022-157766

Back

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Journal article

Peer reviewed

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, …

Blood, Vol.140(Supplement 1), pp.10374-10376

2022-11-15

DOI: https://doi.org/10.1182/blood-2022-157766

Appears in Miller School of Medicine - Latest Publications

Metrics

22 Record Views

2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.916 Epstein-Barr Virus
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Creators: Kris Michael Mahadeo - The University of Texas MD Anderson Cancer Center
Robert A. Baiocchi - The Ohio State University
Amer Beitinjaneh - Jackson Memorial Hospital
Sridhar Chaganti - NIHR Surgical Reconstruction and Microbiology Research Centre
Sylvain Choquet - Pitié-Salpêtrière Hospital
Daan Dierickx - 6University Hospitals Leuven, Leuven, Belgium
Rajani Dinavahi - Atara Biotherapeutics
Laurence Gamelin - Atara Biotherapeutics
Armin Ghobadi - Washington University in St. Louis
Norma Guzman-Becerra - Atara Biotherapeutics
Manher Joshi - Atara Biotherapeutics
Aditi Mehta - Atara Biotherapeutics
Sarah Nikiforow - Dana-Farber Cancer Institute
Ran Reshef - Columbia University Irving Medical Center
Wei Ye - Atara Biotherapeutics
Susan Prockop - Dana–Farber Cancer Institute
Publication Details: Blood, Vol.140(Supplement 1), pp.10374-10376
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031785798302976